(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]-5-[[(2S)-3-carboxy-1-[[(2S)-3-carboxy-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(1R)-1-carboxy-2-sulfanylethyl]amino]-3-[3-(9H-fluoren-9-ylmethylsulfanyl)propanoylamino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid | 926623-18-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]-5-[[(2S)-3-carboxy-1-[[(2S)-3-carboxy-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(1R)-1-carboxy-2-sulfanylethyl]amino]-3-[3-(9H-fluoren-9-ylmethylsulfanyl)propanoylamino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
• CAS: 926623-18-9
• 化学式: C₅₄H₅₉N₁₃O₁₈S₂
• 分子量: 1242.27
• InChiKey: PDBDEKDAHLJNIL-JPRYDEJLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.4
• 重原子数：
  87
• 可旋转键数：
  33
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  522
• 氢给体数：
  16
• 氢受体数：
  24

反应信息

• 作为反应物：
  描述：

  (2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]-5-[[(2S)-3-carboxy-1-[[(2S)-3-carboxy-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(1R)-1-carboxy-2-sulfanylethyl]amino]-3-[3-(9H-fluoren-9-ylmethylsulfanyl)propanoylamino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid 、 vinblastine pyridinyl disulfide 在 碳酸氢钠 作用下， 以 四氢呋喃 为溶剂， 以75%的产率得到
  参考文献：
  名称：

  An Assembly Concept for the Consecutive Introduction of Unsymmetrical Disulfide Bonds:  Synthesis of a Releasable Multidrug Conjugate of Folic Acid

  摘要：

  We describe the development of methodology which allows for the introduction of a second disulfide bond into a molecular framework with a pre-existing disulfide linker system. Compounds which contain an S-9-fluorenylmethyl-protected thiol and an additional disulfide linkage are deprotected in situ and trapped with an activated thiophile. This methodology allowed for the synthesis of the first molecule possessing two different biologically active agents covalently attached to a folate receptor targeting ligand unit via two disulfide-based release systems.

  DOI：

  10.1021/jo070411z
• 作为产物：
  描述：

  Fmoc-Dap(ivDde)-OH 、 N10-三氟乙酰基蝶酸 、 芴甲氧羰基-L-谷氨酸 1-叔丁酯 、 Fmoc-L-天冬氨酸 beta-叔丁酯 、 alkaline earth salt of/the/ methylsulfuric acid 、 alkaline earth salt of/the/ methylsulfuric acid 以450 mg的产率得到(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]-5-[[(2S)-3-carboxy-1-[[(2S)-3-carboxy-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(1R)-1-carboxy-2-sulfanylethyl]amino]-3-[3-(9H-fluoren-9-ylmethylsulfanyl)propanoylamino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
  参考文献：
  名称：

  An Assembly Concept for the Consecutive Introduction of Unsymmetrical Disulfide Bonds:  Synthesis of a Releasable Multidrug Conjugate of Folic Acid

  摘要：

  We describe the development of methodology which allows for the introduction of a second disulfide bond into a molecular framework with a pre-existing disulfide linker system. Compounds which contain an S-9-fluorenylmethyl-protected thiol and an additional disulfide linkage are deprotected in situ and trapped with an activated thiophile. This methodology allowed for the synthesis of the first molecule possessing two different biologically active agents covalently attached to a folate receptor targeting ligand unit via two disulfide-based release systems.

  DOI：

  10.1021/jo070411z

文献信息

• WO2007/22494
  申请人：——

  公开号：——

  公开（公告）日：——
• WO2007/22493
  申请人：——

  公开号：——

  公开（公告）日：——
• Multi-Drug Ligand Conjugates
  申请人：Vlahov Iontcho Radoslavov

  公开号：US20080248052A1

  公开（公告）日：2008-10-09

  Described herein are compounds, pharmaceutical compositions and methods for treating pathogenic cell populations in a patient. The compounds described herein include conjugates of a plurality of cytotoxic drugs and vitamin receptor binding ligands. The plurality of drugs may be the same or different. Similarly, the vitamin receptor binding ligands may be the same or different. The conjugates also include a linker that is formed from one or more spacer linkers, heteroatom linkers, and releasable linkers.
• Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives
  申请人：Leamon Christopher Paul

  公开号：US20080280937A1

  公开（公告）日：2008-11-13

  Described herein are compounds, pharmaceutical compositions and methods for treating pathogenic cell populations in a patient. The compounds described herein include conjugates of cytotoxic drugs and vitamin receptor binding ligands. The conjugates also include a linker that is formed from one or more spacer linkers, heteroatom linkers, and releasable linkers.
• MULTI-DRUG LIGAND CONJUGATES
  申请人：Endocyte, Inc.

  公开号：US20130184435A1

  公开（公告）日：2013-07-18

  Described herein are compounds, pharmaceutical compositions and methods for treating pathogenic cell populations in a patient. The compounds described herein include conjugates of a plurality of cytotoxic drugs and vitamin receptor binding ligands. The plurality of drugs may be the same or different. Similarly, the vitamin receptor binding ligands may be the same or different. The conjugates also include a linker that is formed from one or more spacer linkers, heteroatom linkers, and releasable linkers.